Review
A year of successful cancer vaccines points to a path forward
Affiliations
- PMID: 20140811
Item in Clipboard
Review
A year of successful cancer vaccines points to a path forward
Curr Opin Mol Ther.
2010 Feb.
Abstract
Results from recent clinical trials of the therapeutic vaccines sipuleucel-T (Dendreon Corp), PROSTVAC-VF-TRICOM (National Cancer Institute/BN ImmunoTherapeutics Inc) and BiovaxID (Biovest International Inc) are highlighted. These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer.
Similar articles
-
Therapeutic vaccines for prostate cancer.Curr Opin Mol Ther. 2010 Feb;12(1):77-85. Curr Opin Mol Ther. 2010. PMID: 20140819 Review.
-
Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.Curr Opin Mol Ther. 2007 Apr;9(2):183-9. Curr Opin Mol Ther. 2007. PMID: 17458173
-
Therapeutic cancer vaccines on trial.Nat Biotechnol. 2002 Jul;20(7):659-63. doi: 10.1038/nbt0702-659. Nat Biotechnol. 2002. PMID: 12089545 No abstract available.
-
Cancer vaccines on the horizon.Nat Rev Drug Discov. 2007 May;6(5):333-4. doi: 10.1038/nrd2325. Nat Rev Drug Discov. 2007. PMID: 17539052 No abstract available.
-
A clinical development paradigm for cancer vaccines and related biologics.J Immunother. 2007 Jan;30(1):1-15. doi: 10.1097/01.cji.0000211341.88835.ae. J Immunother. 2007. PMID: 17198079 Review.
Cited by
-
Immunotherapy for Multiple Myeloma.Cancers (Basel). 2019 Dec 12;11(12):2009. doi: 10.3390/cancers11122009. Cancers (Basel). 2019. PMID: 31842518 Free PMC article. Review.
-
Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity.J Transl Med. 2010 Dec 14;8:132. doi: 10.1186/1479-5876-8-132. J Transl Med. 2010. PMID: 21144062 Free PMC article.
-
Oncoantigens for an immune prevention of cancer.Am J Cancer Res. 2011;1(2):255-264. Epub 2010 Dec 20. Am J Cancer Res. 2011. PMID: 21969087 Free PMC article.
-
Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist.Chembiochem. 2014 Jul 7;15(10):1508-13. doi: 10.1002/cbic.201402077. Epub 2014 May 30. Chembiochem. 2014. PMID: 24890740 Free PMC article.
-
DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies.Oncotarget. 2015 Oct 20;6(32):32494-508. doi: 10.18632/oncotarget.5572. Oncotarget. 2015. PMID: 26378812 Free PMC article.